You are here: Home » PTI Stories » National » News
Business Standard

Dr Reddy's ties up with UCB to market epilepsy drug in India

Press Trust of India  |  Hyderabad 

: Limited and UCB, a company, today announced they have entered into a distribution and co-promotion agreement for Briviact (Brivaracetam) for

According to a press release issued by Dr Reddys, the agreement grants it the exclusive right to distribute Briviact in

The drug is approved as an for the treatment of in patients who are 16 years of age and older.

Dr Reddy's - Branded Markets (and Emerging Markets), M V Ramana, said "In our endeavour to make innovative medicines accessible to patients in India, we are excited to with India for Briviact, a novel that will make a difference to the lives of patients living with "

Neurology Patient Value Unit, head of International Markets, said "This partnership is another important step towards us providing value together to patients by making Briviact available as an additional treatment choice for epilepsy."

Epilepsy is the second most common neurological conditionand as per a recent study, an estimated 70 million people suffer from it worldwide while there are over 12 million people suffering from epilepsy in India, which contributes to nearly one-sixth of the global burden, the release said.

DR Reddys share closed at Rs 2329.80 apiece, up by 2.80 per cent over previous close on the

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, July 09 2018. 16:20 IST